Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Malaria is one of the world’s oldest known diseases, but it is a modern disease too - it continues to kill roughly 600,000 people each year. Most of these people are children, living in Sub-Saharan Africa.

A doctor and a young girl in Africa

The theme of this year’s World Malaria Day (marked on 25 April) is ‘Driven to end malaria’. One way that scientists and health workers are doing this is by giving anti-malarial drugs (medicines that kill the malaria parasites) to healthy young children during the malaria ‘high season’ - before they actually get sick from malaria. Every year, 50 million children in Africa are treated with this seasonal malaria chemoprevention.

This is a really practical intervention: it uses relatively cheap medicines, and it targets the most vulnerable group – young children - at times of the year when their risk of getting malaria is highest. Crucially, health workers give these medicines directly to children in their communities - parents don’t to travel to health centres to get these life-saving medications, an important consideration in many rural parts of world, where health centres are a long way away and difficult and expensive to get to. 

Making things better

At the Infectious Diseases Data Observatory at Oxford University, they are working to make this malaria preventative treatment even better. They do this effectively and cheaply by bringing together data from multiple studies, then analysing it to produce robust scientific evidence that health policy makers can actually use. 

As part of his DPhil, Dhruv Darji (Nuffield Department of Medicine and Infectious Diseases Data Observatory (IDDO)is evaluating what combinations of antimalarial drugs, including combinations with malaria vaccines, work best for this kind of preventative malaria medication. Normally, you might figure this with a clinical trial where we test out all of these combinations to find out which ones work best. But clinical trials are expensive, even more so in a resource-limited settings in Africa, and the few clinical studies that do exist aren’t enough to provide a comprehensive answer.

 

Read the full story on the University of Oxford website. 

 

Similar stories

Exceptional early-career researchers awarded 2026 European Research Council Starting Grants

Four University of Oxford researchers have been awarded prestigious European Research Council (ERC) Starting Grants, each worth €1.5 million for a period of up to five year

How body fat is stored across organs may reveal hidden health risks, study suggests

Researchers from the Nuffield Department of Population Health and the University of Oxford’s Big Data Institute have contributed to a new study showing that how fat accumulates in the body is just as important for identifying different health risks as a person’s overall weight.

Four Oxford researchers recognised in the 2026 Royal Society Awards

The annual Royal Society Awards recognise outstanding contributions to scientific discovery, public engagement and research culture. Of the 27 awards for 2025-26, announced today, four honour Oxford University researchers.

New shingles vaccine linked to lower risk of coronary heart disease, stroke and heart failure – major study indicates

The shingles vaccine currently in use, called ‘Shingrix’, is associated with a reduced risk of cardiovascular events – including heart attacks, heart failure and stroke – compared to the previous shingles vaccine, according to a major new study published in Nature Medicine.

Vapes help more people quit smoking than other methods, Oxford-led Cochrane review finds

An updated Cochrane review led by Oxford researchers finds nicotine e-cigarettes help more people quit smoking than nicotine patches and gum, behavioural support or no support. The living review now includes 80 trials and nearly 30,000 participants.

Brain imaging study reveals how we decide whether we are in control

A brain imaging and stimulation study led by the University of Oxford has identified the brain mechanisms that help us work out whether the consequences we experience are caused by our own actions or by circumstances beyond our control.